Tomer Meirson

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 27

Top Topics

Psychometric Properties

Top Venues

BMJ (Clinical research ed.)

Bioinformatics (Oxford, England)

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Roni Gurvich, Gal Markel, Ziaurrehman Tanoli, Tomer Meirson
Peptriever: a Bi-Encoder approach for large-scale protein-peptide binding search. Bioinformatics (Oxford, England) 40 (5) (2024)
Roni Gurvich, Gal Markel, Ziaurrehman Tanoli, Tomer Meirson
Peptriever: a Bi-Encoder approach for large-scale protein-peptide binding search. Bioinformatics (Oxford, England) 40 (5) (2024)
Eric J Hsu, Timothy A Lin, Dor R Dabush, Zachary McCaw, Alex Koong, Christine Lin, Joseph Abi Jaoude, Roshal Patel, Ramez Kouzy, Molly B El Alam, Sonal Noticewala, Yumeng Yang, Alexander D Sherry, Clifton D Fuller, Charles R Thomas, Chad Tang, Pavlos Msaouel, Prajnan Das, Bo Huang, Lu Tian, Ryan Sun, J Jack Lee, Tomer Meirson, Ethan Bernard Ludmir
Association of differential censoring with survival and suboptimal control arms among oncology clinical trials. Journal of the National Cancer Institute 116 (6) (2024)
Timothy A Lin, Zachary Ryan McCaw, Alex Koong, Christine Lin, Joseph Abi Jaoude, Roshal R Patel, Ramez Kouzy, Molly B El Alam, Alexander D Sherry, Sonal S Noticewala, Clifton David Fuller, Charles R Thomas, Ryan Sun, Jiun-Kae Jack Lee, Ruitao Lin, Ying Yuan, Yu Shyr, Tomer Meirson, Ethan Bernard Ludmir
Proportional Hazards Violations in Phase 3 Cancer Clinical Trials: A Potential Source of Trial Misinterpretation. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Roni Gurvich, Gal Markel, Ziaurrehman Tanoli, Tomer Meirson
Peptriever: a Bi-Encoder approach for large-scale protein-peptide binding search. Bioinformatics (Oxford, England) 40 (5) (2024)
Ian F Tannock, Daniel A Goldstein, Jonathan Ofer, Bishal Gyawali, Tomer Meirson
Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Nir Balaban, Ghulam Rehman Mohyuddin, Adi Kashi, Amir Massarweh, Gal Markel, David Bomze, Daniel A Goldstein, Tomer Meirson
Projecting complete redaction of clinical trial protocols (RAPTURE): redacted cross sectional study. BMJ (Clinical research ed.) 383 (2023)
Valerio Nardone, Tomer Meirson, Francesca De Felice, Icro Meattini
Genomic Profiling: Can We Rely on Retrospective Analysis to Drive Changes in Clinical Practice? Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Nir Balaban, Ghulam Rehman Mohyuddin, Adi Kashi, Amir Massarweh, Gal Markel, David Bomze, Daniel A Goldstein, Tomer Meirson
Projecting complete redaction of clinical trial protocols (RAPTURE): redacted cross sectional study. BMJ (Clinical research ed.) 383 (2023)
Nir Balaban, Ghulam Rehman Mohyuddin, Adi Kashi, Amir Massarweh, Gal Markel, David Bomze, Daniel A Goldstein, Tomer Meirson
Projecting complete redaction of clinical trial protocols (RAPTURE): redacted cross sectional study. BMJ (Clinical research ed.) 383 (2023)
Nir Balaban, Ghulam Rehman Mohyuddin, Adi Kashi, Amir Massarweh, Gal Markel, David Bomze, Daniel A Goldstein, Tomer Meirson
Projecting complete redaction of clinical trial protocols (RAPTURE): redacted cross sectional study. BMJ (Clinical research ed.) 383 (2023)
Nir Balaban, Ghulam Rehman Mohyuddin, Adi Kashi, Amir Massarweh, Gal Markel, David Bomze, Daniel A Goldstein, Tomer Meirson
Projecting complete redaction of clinical trial protocols (RAPTURE): redacted cross sectional study. BMJ (Clinical research ed.) 383 (2023)
Nir Balaban, Ghulam Rehman Mohyuddin, Adi Kashi, Amir Massarweh, Gal Markel, David Bomze, Daniel A Goldstein, Tomer Meirson
Projecting complete redaction of clinical trial protocols (RAPTURE): redacted cross sectional study. BMJ (Clinical research ed.) 383 (2023)
Tomer Meirson, David Bomze, Ora Schueler-Furman, Salomon M Stemmer, Gal Markel
Systemic structural analysis of alterations reveals a common structural basis of driver mutations in cancer. NAR cancer 5 (1) (2023)
Alessandro Genna, Joel Alter, Martina Poletti, Tomer Meirson, Tal Sneh, Michal Gendler, Natalia Saleev, George S Karagiannis, Yarong Wang, Dianne Cox, David Entenberg, Maja H Oktay, Tamas Korcsmaros, John S Condeelis, Hava Gil-Henn
FAK family proteins regulate in vivo breast cancer metastasis via distinct mechanisms. bioRxiv : the preprint server for biology (2023)
Tomer Meirson, David Bomze, Ora Schueler-Furman, Salomon M Stemmer, Gal Markel
Systemic structural analysis of alterations reveals a common structural basis of driver mutations in cancer. NAR cancer 5 (1) (2023)
Shams Twafra, Chana G Sokolik, Tal Sneh, Kolluru D Srikanth, Tomer Meirson, Alessandro Genna, Jordan H Chill, Hava Gil-Henn
Correction: A novel Pyk2-derived peptide inhibits invadopodia-mediated breast cancer metastasis. Oncogene (2022)
Shams Twafra, Chana G Sokolik, Tal Sneh, Kolluru D Srikanth, Tomer Meirson, Alessandro Genna, Jordan H Chill, Hava Gil-Henn
Correction: A novel Pyk2-derived peptide inhibits invadopodia-mediated breast cancer metastasis. Oncogene (2022)
Naama Margolis, Hanna Moalem, Tomer Meirson, Gilli Galore-Haskel, Ettai Markovits, Erez Nissim Baruch, Bella Vizel, Avner Yeffet, Julia Kanterman-Rifman, Assaf Debby, Michal J Besser, Jacob Schachter, Gal Markel
Adenosine-Deaminase-Acting-on-RNA-1 Facilitates T-cell Migration toward Human Melanoma Cells. Cancer immunology research 10 (9) (2022)
Shams Twafra, Chana G Sokolik, Tal Sneh, Kolluru D Srikanth, Tomer Meirson, Alessandro Genna, Jordan H Chill, Hava Gil-Henn
A novel Pyk2-derived peptide inhibits invadopodia-mediated breast cancer metastasis. Oncogene (2022)
Tomer Meirson, David Bomze, Gal Markel
Structural basis of SARS-CoV-2 spike protein induced by ACE2. Bioinformatics (Oxford, England) 37 (7) (2021)
Tomer Meirson, Nethanel Asher, David Bomze, Gal Markel
Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation. Cancers 12 (6) (2020)
Nethanel Asher, Guy Ben-Betzalel, Shaked Lev-Ari, Ronnie Shapira-Frommer, Yael Steinberg-Silman, Neta Gochman, Jacob Schachter, Tomer Meirson, Gal Markel
Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma. Cancers 12 (8) (2020)
Shira Perez, Antony Kaspi, Tom Domovitz, Ateret Davidovich, Anat Lavi-Itzkovitz, Tomer Meirson, Jacinta Alison Holmes, Chia-Yen Dai, Chung-Feng Huang, Raymond T Chung, Assy Nimer, Assam El-Osta, Gur Yaari, Salomon M Stemmer, Ming-Lung Yu, Izhak Haviv, Meital Gal-Tanamy
Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. PLoS genetics 15 (6) (2019)
Tomer Meirson, Hava Gil-Henn, Abraham O Samson
Invasion and metastasis: the elusive hallmark of cancer. Oncogene 39 (9) (2019)
Alessandro Genna, Stefanie Lapetina, Nikola Lukic, Shams Twafra, Tomer Meirson, Ved P Sharma, John S Condeelis, Hava Gil-Henn
Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells. The Journal of cell biology 217 (1) (2017)
Yitav Glantz-Gashai, Tomer Meirson, Abraham O Samson
Normal Modes Expose Active Sites in Enzymes. PLoS computational biology 12 (12) (2016)